#$%^&*AU2017200998A120170309.pdf#####ABSTRACT: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration5 resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody D11 7E6 and structural mutants thereof. 8718549_1 (GHMatters) P94251.AU.1
